Kumar, Dulla Naveen; Chaudhuri, Aiswarya; Dehari, Deepa; Shekher, Anusmita; Gupta, Subash C.; Majumdar, Shreyasi; Krishnamurthy, Sairam; Singh, Sanjay; Kumar, Dinesh; Agrawal, Ashish Kumar
(MDPI, 2022-08)
Paclitaxel (PAC) has been approved by FDA for clinical use (Taxol®), yet dose-dependent severe toxicity due to the adjuvant Cremophor EL® in combination with ethanol is a major drawback. The drawbacks of the current therapy ...